VVOS News & Events

Vivos Therapeutics announced that an a recent published study supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea, or OSA, in adults and children. Vivos CARE devices have been cleared by the FDA for adult patients diagnosed with mild, moderate and severe OSA and moderate-to-severe OSA in children ages 6 to 17. Many Vivos patients finish treatment in less than 12 months with little or no remaining OSA symptoms. The OSA group exhibited significantly narrower transverse intermolar distance and higher palatal height compared to the control group. Linear regression analysis demonstrated a strong association between these two key craniofacial parameters and OSA severity, as measured by the industry standard measure AHI. These results held true across all demographics.

Vivos Therapeutics files to sell 3.96M shares of common stock for holders

Vivos Therapeutics has entered into a 12-part media series agreement with New to The Street.

Vivos Therapeutics and SoundHealth announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' national network of over 2,000 Vivos-trained dentists and sleep healthcare providers, along with affiliated sleep testing centers in select markets, to distribute SoundHealth's Sonu platform.